18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment

Launched by CENTRE DE RECHERCHE DU CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE · Apr 8, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging method called 18F-sodium fluoride (18F-NaF) to see if it can safely replace the current standard test for looking at bone problems, known as bone scintigraphy. This trial is particularly important because there has been a shortage of materials needed for the standard test, and 18F-NaF could offer a reliable alternative. The trial aims to assess how safe 18F-NaF injections are and will also create a registry of patients to gather more information about how well this method works for different bone and joint diseases.

To participate in this study, individuals must be candidates for the standard bone scintigraphy test, which is often used for conditions like bone cancer or infections. Patients of all ages are welcome, including children who need this test for oncological or infectious reasons. Participants should be able to lie flat for at least 15 minutes and must give written consent to join the study. If you have any allergies to 18F-NaF or are pregnant, you would not be eligible to participate. Overall, this trial is an exciting opportunity to help improve the way we diagnose and monitor bone-related health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated;
• • Pediatric patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated for oncologic or infectious reasons
• • Able to tolerate supine position
• • Written consent
• Exclusion Criteria:
• • Healthy subjects
• • Pregnancy
• • Unable of maintaining supine position for more than 15 minutes
• • Refusal to sign the consent form
• • Known allergy or hypersensitivity to 18F-NaF or any of its constituants.